CD274 and neoplasm: TNBC is the most immunogenic subtype of breast cancer with higher levels of PD-L1 expression and tumor infiltrating lymphocytes (TILs) than other subtypes, suggesting that it is more likely to benefit from treatment with ICIs [27].